USPTO serial 87978084
NAVICAN PRECISION CANCER CARE
Reviewed by CopyMark Law Group
Reg. 5771248Status 710
- Filing date
- Status date
- Registration date
- Jun 4, 2019
- Examiner
- LEASER,ANDREW C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with NAVICAN PRECISION CANCER CARE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Diego, CA
SALT LAKE CITY, UT
San Diego, CA
San Diego, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joshua G. Gigger
JOSHUA G. GIGGER STOEL RIVES LLPONE UTAH CENTER201 SOUTH MAIN STREET, SUITE 1100SALT LAKE CITY, UT 84111Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Medical, clinical and scientific research in the field of oncology, namely, research relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; scientific and technological services, namely, research services for medical purposes in the field of genetic diagnostic assays and pharmaceuticals research for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information and scientific consulting in the field of genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; conducting early evaluations in the field of new genetic diagnostics assays and pharmaceuticals; development, evaluation and medical and scientific research of genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; laboratory research services relating to genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals, clinical trials and genetics; technical consulting related to scientific and medical studies in the field of genetic diagnostic assay and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; basic and clinical research in the field of oncology, namely, researching genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals and clinical trials for personalized diagnosis, treatment and prevention of cancer; custom design and development of chemical reagants and multiplex sequencing assays for personalized diagnosis, treatment and prevention of cancer; providing an on-line computer database featuring medical and scientific research information in the field of oncology that allows for input and collection of scientific and research data and information relating to genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, data mining and pattern recognition, designing clinical studies, and generating genomic data from patient samples for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific clinical data and scientific clinical studies relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection of mathematical and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to cancer treatments for personalized diagnosis, treatment and prevention of cancer; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies for personalized diagnosis, treatment and prevention of cancer; providing a website featuring technology with a web-based interface where medical professionals can view genetic test results and interpretations of the results by scientists and medical professionals in the field of genomics, and select the appropriate treatment and order the necessary pharmaceutical products | SECTION 8 - CANCELLED | Apr 23, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Navican Genomics, Inc.
- Other trademarks owned by IHC HEALTH SERVICES, INC.
- Other trademarks owned by Navican Genomics, Inc.
- Other trademarks owned by Navican Genomics, Inc.
- Other trademarks in Class 042
- Similar marks named NAVICAN PRECISION CANCER CARE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 19, 2025 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jun 4, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Aug 14, 2019 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jun 4, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 3, 2019 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| May 2, 2019 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| May 2, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 2, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 2, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 2, 2019 | SNEA | SU-EXAMINER'S AMENDMENT WRITTEN | — |
| Oct 4, 2018 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 4, 2018 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 4, 2018 | CNFR | SU - FINAL REFUSAL - WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 14, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 13, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 13, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 2, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 2, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 2, 2018 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 16, 2018 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jul 16, 2018 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Jul 16, 2018 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 29, 2018 | IUAF | USE AMENDMENT FILED | — |
| Jun 29, 2018 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Jun 29, 2018 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Jun 29, 2018 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 2, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 7, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 7, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 18, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 1, 2017 | ALIE | ASSIGNED TO LIE | — |
| Sep 16, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 26, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 26, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 26, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 26, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 24, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 24, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 24, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 24, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 17, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 6, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 2, 2017 | NWAP | NEW APPLICATION ENTERED | — |